Vertex: povetacicept cut IgAN proteinuria 52% in trial
According to TradingView, povetacicept reduced IgAN proteinuria by 52% at week 36, while AMPLITUDE interim results are expected early next year.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, the AMPLITUDE study is fully enrolled, with interim results expected early next year. At week 36, the drug povetacicept lowered proteinuria in IgA nephropathy by 52%. Discussions with the FDA are anchored to one-year eGFR data.
why it matters
For Vertex, the key driver right now is the IgAN program, so investors will focus on the interim data and talks with regulators. Coverage announcements from payers are expected in H1 2027. The story concerns one company and has little direct effect on the broader market.
market impact
Vertex (VRTX): IgAN drug news keeps the focus on the company's shares and pipeline
tags
instruments
sources
- VRTX: Povetacicept cut IgAN proteinuria 52%; AMPLITUDE interim results are due early next year — TradingView, 24 October 2026 at 02:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗